Early Promise From Axovant’s Parkinson’s Gene Therapy
But Investors Spooked By Incomplete Results
Gene therapy shows promise in treating movement disorders in 4 patients, matching longer-term results from rivals Neurocrine Biosciences and Voyager Therapeutics.
You may also be interested in...
Many clinicians doubt that aducanumab can really help slow the decline in Alzheimer’s patients – but US FDA could offer it the benefit of the doubt.
Timing means full EU approval could coincide with US FDA authorization later this year.
Vertex has become a biotech investor favorite amid the tumult of 2020, but the potential of its pipeline is now under question.